Equities Analysts Offer Predictions for InflaRx Q3 Earnings

Key Points

• HC Wainwright analysts predict InflaRx will report Q3 2025 earnings of $0.13 per share, maintaining a "Buy" rating with a price target of $6.00.
• InflaRx's stock has an average rating of "Buy" among five analysts, with a consensus target price of $6.20, despite several recent target price reductions by other firms.
• The company reported revenues of $0.05 million in its last earnings release, matching the analysts' expectations, as it continues to develop its lead product candidate, vilobelimab.

InflaRx N.V. (NASDAQ:IFRX - Free Report) - Research analysts at HC Wainwright issued their Q3 2025 EPS estimates for InflaRx in a research report issued to clients and investors on Tuesday, September 2nd. HC Wainwright analyst M. Keller forecasts that the company will post earnings per share of ($0.13) for the quarter. HC Wainwright has a "Buy" rating and a $6.00 price objective on the stock. The consensus estimate for InflaRx's current full-year earnings is ($1.04) per share. HC Wainwright also issued estimates for InflaRx's Q4 2025 earnings at ($0.20) EPS, FY2025 earnings at ($0.73) EPS, FY2026 earnings at ($0.71) EPS, FY2027 earnings at ($0.71) EPS and FY2028 earnings at ($0.72) EPS.

Several other equities research analysts have also weighed in on IFRX. Raymond James Financial lowered shares of InflaRx from a "strong-buy" rating to an "outperform" rating and set a $2.00 target price on the stock. in a report on Thursday, May 29th. Oppenheimer dropped their price objective on shares of InflaRx from $6.00 to $3.00 and set an "outperform" rating on the stock in a report on Thursday, May 29th. Five analysts have rated the stock with a Buy rating, Based on data from MarketBeat.com, InflaRx has an average rating of "Buy" and a consensus target price of $6.20.

InflaRx Stock Performance

IFRX opened at $1.73 on Thursday. The firm's fifty day moving average is $0.93 and its two-hundred day moving average is $1.14. The firm has a market cap of $116.14 million, a PE ratio of -2.16 and a beta of 1.43. InflaRx has a twelve month low of $0.71 and a twelve month high of $2.82.

InflaRx (NASDAQ:IFRX - Get Free Report) last posted its earnings results on Thursday, August 7th. The company reported ($0.24) earnings per share for the quarter, hitting the consensus estimate of ($0.24). The firm had revenue of $0.05 million during the quarter, compared to analyst estimates of $0.02 million.

Institutional Investors Weigh In On InflaRx

Hedge funds and other institutional investors have recently added to or reduced their stakes in the business. Cubist Systematic Strategies LLC acquired a new stake in InflaRx in the 4th quarter valued at $55,000. XTX Topco Ltd acquired a new stake in InflaRx in the 1st quarter valued at $38,000. Concurrent Investment Advisors LLC acquired a new stake in InflaRx in the 2nd quarter valued at $65,000. OCONNOR A Distinct Business Unit of UBS ASSET MANAGEMENT AMERICAS LLC increased its stake in InflaRx by 158.3% in the 2nd quarter. OCONNOR A Distinct Business Unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 150,000 shares of the company's stock valued at $118,000 after buying an additional 91,927 shares during the last quarter. Finally, Adage Capital Partners GP L.L.C. acquired a new stake in InflaRx in the 2nd quarter valued at $262,000. 42.39% of the stock is currently owned by institutional investors and hedge funds.

About InflaRx

InflaRx N.V., a clinical-stage biopharmaceutical company, discovers and develops inhibitors using C5a technology in Germany and the United States. The company's C5a is an inflammatory mediator that is involved in the progression of a variety of autoimmune and other inflammatory diseases. Its lead product candidate is vilobelimab, a novel intravenously delivered first-in-class anti-C5a monoclonal antibody, which completed the Phase III clinical trial for the treatment of hidradenitis suppurativa, a rare and chronic debilitating systemic inflammatory skin disease; for the treatment of anti-neutrophil cytoplasm antibody associated vasculitis, a rare and life-threatening autoimmune disease that is in Phase II trial; to treat pyoderma gangraenosum, a chronic inflammatory skin disorder that is in Phase IIa exploratory study; and for the treatment of PD-1/PD-L1 inhibitor resistant/refractory locally advanced or metastatic cutaneous squamous cell carcinoma that is in Phase II clinical development stage.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.